A61K38/4893

NEUROTOXIN COMPOSITIONS FOR USE IN TREATING GASTROPARESIS
20220331410 · 2022-10-20 ·

Disclosed herein are compositions and methods for use in treating gastroparesis.

COMBINATION THERAPY WITH CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES
20230105611 · 2023-04-06 ·

Methods for treating headache, migraine and related symptoms by administering a CGRP antagonist and a Clostridial derivative are described.

METHODS FOR TREATING AND FOR INHIBITING PROGRESSION OF SEIZURES
20230147214 · 2023-05-11 ·

Methods for treating seizures and for inhibiting progression of a focal seizure to a generalized seizure by administering extracranially a Clostridial derivative are described.

NEUROTOXIN COMPOSITIONS FOR USE IN TREATING CARDIOVASCULAR DISORDERS
20230145940 · 2023-05-11 ·

Disclosed herein are compositions and methods for use in treating cardiovascular disorders.

Composition comprising recombinant clostridium neurotoxin

The invention provides methods for producing soluble di-chain BoNT/A protein.

VIRAL VECTORS FOR TREATING NEUROGENIC DETRUSOR OVERACTIVITY

The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.

Modified non-cytotoxic proteases

The present invention relates to a modified polypeptide comprising a non-cytotoxic protease, a translocation domain, a destructive protease cleavage site and a Targeting Moiety that binds to a Binding Site on a nerve cell, wherein after cleavage of the destructive cleavage site the polypeptide has reduced potency. The destructive cleavage site is recognized and cleaved by a protease present at or in an off-site target cell, and, in one embodiment, the polypeptide is a modified clostridial neurotoxin. The present invention also relates to the use of said polypeptides for treating a range of conditions, and to nucleic acids encoding said polypeptides.

Degradable clostridial toxins

The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.

STABILIZED AND SOLUBILIZED DRUG FORMULATION FOR TOPICAL APPLICATION AND TRANSDERMAL EFFICACY FOR COSMETIC IMPROVEMENT AND METHODS OF FORMULATION
20170361130 · 2017-12-21 ·

The invention relates to a novel stabilized and solubilized topical formulation for cosmetic improvements and methods of making the same comprising multiplexed molecular penetration enhancers and essential and semi-essential amino acid protein binders for the topical application and transdermal delivery of one or more active ingredients and/or pharmaceutical agents. The invention further relates to the use of the topical formulation in connection with the providing of cosmetic improvements in individuals.

METHOD FOR DELIVERY OF BIOLOGIC AGENTS FROM A TOPICAL FORMULATION

Methods for delivery of a biologic agent to the dermis or superficial muscles by topical application of the agent are provided. The methods comprise, in one embodiment, treating or conditioning a skin area to disrupt the stratum corneum in the skin area to define a treated skin area and applying a formulation comprising a biologic agent to the treated skin area.